Anticoagulation for venous thromboembolism [3] (multiple letters)

New England Journal of Medicine

Volumn 341, Issue 7, 1999, Pages 539-540

  Bucciarelli, P ^a   Alatri, A ^a   Moia, M ^a   Khamashta, M A ^a   Williams, F M K ^a   Hunt, B J ^a   Kearon, C ^a   Ginsberg, J S ^a   Gent, M ^a  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

WARFARIN; ANTICOAGULANT AGENT;

ANTICOAGULATION; ANTIPHOSPHOLIPID SYNDROME; FOLLOW UP; HEALTH CARE COST; HUMAN; HUMAN CELL; HUMAN TISSUE; LETTER; PRIORITY JOURNAL; QUALITY OF LIFE; RECURRENCE RISK; RISK BENEFIT ANALYSIS; THROMBOSIS PREVENTION; VEIN THROMBOSIS; DRUG ADMINISTRATION; NOTE; RECURRENT DISEASE;

ANTICOAGULANTS; DRUG ADMINISTRATION SCHEDULE; HUMANS; RECURRENCE; VENOUS THROMBOSIS; ANTIPHOSPHOLIPID SYNDROME;

EID: 0033549714     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199908123410716     Document Type: Letter

References (0)